Omalizumab antibody | AbD20669_hIgG1
A microtiter plate was coated overnight with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, Human Anti-Omalizumab:HRP Antibody, clone AbD20669_hIgG1 (HCA235P) was added at a concentration of 2 μg/ml. Detection was performed using QuantaBlu Fluorogenic Peroxidase Substrate.
A microtiter plate was coated overnight with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, Human Anti-Omalizumab:HRP Antibody, clone AbD20669_hIgG1 (HCA235P) was added titrated to the given concentrations in PBST + 10% Human Serum. Detection was performed using QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
A microtiter plate was coated overnight with omalizumab at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, Human Anti-Omalizumab Antibody, clone AbD20669_hIgG1 (HCA235) in PBST + 10% Human Serum (black) or in PBST without Human Serum (red) were added. Detection was performed using HRP conjugated omalizumab and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements. The addition of serum influences the binding curve of the assay due to interference from endogenous IgE.
A microtiter plate was coated overnight with Human Anti-Omalizumab Antibody, clone AbD20669 (HCA236) at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% Human Serum was added spiked with increasing concentrations of omalizumab. Detection was performed by Human Anti-Omalizumab:HRP Antibody, clone AbD20669_hIgG1 (HCA235P) at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human anti Omalizumab:HRP
Anti-omalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in full IgG1 format; it is ideal for bioanalytical assays for omalizumab and biosimilars. It is suitable as detection antibody in PK bridging ELISA with HCA236 to detect free drug, and as an ADA assay reference standard.
Human anti Omalizumab
Anti-omalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in full IgG1 format; it is ideal for bioanalytical assays for omalizumab and biosimilars. It is suitable as detection antibody in PK bridging ELISA with HCA236 to detect free drug, and as an ADA assay reference standard.
- Product Type
- Monoclonal Antibody
- Clone
- AbD20669_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Datasheet | MSDS | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|---|
| HCA235P | E | 0.1 mg | ||||
| HCA235G | E | 1 mg | ||||
| HCA235 | E | 0.1 mg |
Human Anti-Omalizumab Antibody, clone AbD20669_hIgG1 is a paratope specific, anti-idiotypic antibody that binds specifically to omalizumab but not to free IgE or the drug/immunoglobulin complex. The antibody can be used to measure the levels of omalizumab and biosimilar products in bioanalytical assays.
Clone AbD20669_hIgG1 can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, HRP-conjugated and in full immunoglobulin (Ig) format, is recommended as the detection antibody, paired with the antibody in monovalent Fab format, clone AbD20669 (HCA236), as the capture antibody. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.
Omalizumab (brand name Xolair) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.
Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit.
View a summary of all Anti-Omalizumab Antibodies
Clone AbD20669_hIgG1 can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, HRP-conjugated and in full immunoglobulin (Ig) format, is recommended as the detection antibody, paired with the antibody in monovalent Fab format, clone AbD20669 (HCA236), as the capture antibody. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.
Omalizumab (brand name Xolair) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.
Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit.
View a summary of all Anti-Omalizumab Antibodies
Product Details
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Omalizumab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD = 1.1 nM by real time, label free molecular interaction analysis on immobilized omalizumab.
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Pack Size: 1 mgIgG concentration 1.0 mg/mlPack Size: 0.1 mgIgG concentration 0.5 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Shelf Life
- 12 months from date of despatch
- Shelf Life
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents.
This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Xolair® is a registered trademark of Novartis. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Omalizumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in direct ELISA and as a detection reagent in PK bridging assay together with HCA236 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug - ELISA
- This product may be used as bridging reagent in ADA assay development or, following HRP-conjugation, as a detection reagent in PK assay development together with HCA236 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
Protocol: ADA bridging ELISA
Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Recombinant Human IgE Lambda | HCA171 | 0.1 mg | E | ||
| Recombinant Human IgE Kappa | HCA190 | 0.1 mg | E | ||
| Human anti Omalizumab | HCA236 | 0.1 mg | E | ||
| Human anti Omalizumab (Drug/Target Complex) | HCA237 | 0.1 mg | E | ||
| Human anti Omalizumab (Drug/Target Complex) | HCA238 | 0.1 mg | E | ||
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Recombinant Human IgE Lambda | HCA171 | 0.1 mg | E | ||
| Recombinant Human IgE Kappa | HCA190 | 0.1 mg | E | ||
| Human anti Omalizumab | HCA236 | 0.1 mg | E | ||
| Human anti Omalizumab (Drug/Target Complex) | HCA237 | 0.1 mg | E | ||
| Human anti Omalizumab (Drug/Target Complex) | HCA238 | 0.1 mg | E | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | 3 Conjugations For 400µg Antibody | CJ |
Product Specific References
References for Omalizumab antibody
-
Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
US Patent application US20170315118A1
